Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T Vogl, Shebli Atrash, Sarah A Holstein, Omar Nadeem, Don M Benson, Jr, Maria Chaudhry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Christine Collins, Xavier Parot, Jonathan L Kaufman

Blood blood.2024026124.

https://doi.org/10.1182/blood.2024026124

Published: 2024

Includes: Supplemental data

Journal Articles

Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis

Debashree Basudhar, Dante Descalzi-Montoya, Hao Tang, Minshi Wang, Fan Wu, P. Leif Bergsagel, Xavier Leleu, Daniela Hosseyni, Maria Chaudhry, Nathan Martin, Ethan G. Thompson

Blood (2024) 144 (Supplement 1): 3382.

https://doi.org/10.1182/blood-2024-198740

Published: 2024

Journal Articles

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Blood (2024) 144 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2024-200829

Published: 2024

Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Blood (2023) 142 (Supplement 1): 2101.

https://doi.org/10.1182/blood-2023-173970

Published: 2023

Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Blood (2022) 140 (Supplement 1): 7301–7303.

https://doi.org/10.1182/blood-2022-164877

Published: 2022

Journal Articles

Effect of Age on Outcomes of Allogeneic Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood (2021) 138 (Supplement 1): 3933.

https://doi.org/10.1182/blood-2021-146334

Published: 2021

Journal Articles

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

Dan T. Vogl, Jonathan L. Kaufman, Sarah A. Holstein, Shebli Atrash, Omar Nadeem, Murali Janakiram, Kaveri Suryanarayan, Yuyin Liu, Sabrina Collins, Xavier Parot, Maria Chaudhry

Blood (2021) 138 (Supplement 1): 898.

https://doi.org/10.1182/blood-2021-148463

Published: 2021

Journal Articles

Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias

Zachary Braunstein, Miguel Ruiz, Eric McLaughlin, Naresh Bumma, Don M Benson, Jr., Srinivas Devarakonda, Maria Chaudhry, Abdullah Khan, Francesca Cottini, John C. Reneau, Pierluigi Porcu, Anjali Mishra, Ashley E. Rosko, Jonathan E Brammer

Blood (2021) 138 (Supplement 1): 2449.

https://doi.org/10.1182/blood-2021-152556

Published: 2021

Journal Articles

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2757.

https://doi.org/10.1182/blood-2021-145903

Published: 2021

Journal Articles

Early Versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma

Jordan Nunnelee, Muhammad Salman Faisal, Qiuhong Zhao, Francesca Cottini, Patrick Elder, Ashley E. Rosko, Maria Chaudhry, Abdullah Khan, Srinivas Devarakonda, Naresh Bumma, Don M Benson, Jr., Yvonne A. Efebera, Nidhi Sharma

Blood (2021) 138 (Supplement 1): 3796.

https://doi.org/10.1182/blood-2021-146698

Published: 2021

Journal Articles

Comparison of Bone Marrow Versus Peripheral Blood in Haploidentical Transplantation Using Post-Transplant Cyclophosphamide- a Retrospective Analysis

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-138966

Published: 2020

Journal Articles

TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma

Dan T. Vogl, MD, Jonathan L. Kaufman, MD, Sara A. Holstein, MDPhD, Omar Nadeem, MD, Elizabeth O'Donnell, MD, Kaveri Suryanarayan, MD, Sabrina Collins, Xavier Parot, MD, Maria Chaudhry, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-141219

Published: 2020

Journal Articles

Trend in Survival in Patients Undergoing Allogeneic Stem Cell Transplantation: An Institutional Experience

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-138548

Published: 2020

Journal Articles

Impact of Race and Geographic Location on Outcomes in Allogeneic Transplant

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140012

Published: 2020

Journal Articles

Impact of Chronic Graft-Versus-Host Disease on Non-Relapse Mortality

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-138755

Published: 2020

Journal Articles

Improvement in Survival of AML and MDS Patients Following Allogeneic Transplant: A Long-Term Institutional Experience

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-139933

Published: 2020

Journal Articles

Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma

Filiz Yucebay, PharmD, BCPS, BCOP, Ashleigh Keiter, MS, Qiuhong Zhao, MS, Alison Neal, Nita Williams, Nidhi Sharma, PhD, Francesca Cottini, MD, Maria Chaudhry, MD, Ashley Rosko, MD, Don M. Benson, Jr., MD PhD, Yvonne A. Efebera, MD MPH, Naresh Bumma, MD, Abdullah Khan, MBBS, MSc, Srinivas Devarakonda, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141105

Published: 2020

Journal Articles

Survival Implications of Opioid Use after Blood and Marrow Transplantation

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-134463

Published: 2020

Journal Articles

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Michael Ozga, MD, Qiuhong Zhao, MS, Don M. Benson, Jr., MD PhD, Patrick Elder, MS, Nita Williams, Naresh Bumma, MD, Ashley E. Rosko, MD, Maria Chaudhry, MD, Abdullah Mohammad Khan, MBBS,MSc, Srinivas Devarakonda, MD, Rami Kahwash, MD, Ajay Vallakati, MD, Courtney Campbell, MD PhD, Samir Parikh, MD, Salem Almaani, MD, Jason Prosek, MD, Elyse Redder, PT, CLT-LANA, Yvonne A. Efebera, MD MPH, Nidhi Sharma, PhD

Blood (2019) 134 (Supplement_1): 1833.

https://doi.org/10.1182/blood-2019-124206

Published: 2019

Journal Articles

AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

Blood (2019) 134 (Supplement_1): 2029.

https://doi.org/10.1182/blood-2019-130307

Published: 2019

NARROW

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Effect of Age on Outcomes of Allogeneic Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Early Versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma

Comparison of Bone Marrow Versus Peripheral Blood in Haploidentical Transplantation Using Post-Transplant Cyclophosphamide- a Retrospective Analysis

TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma

Trend in Survival in Patients Undergoing Allogeneic Stem Cell Transplantation: An Institutional Experience

Impact of Race and Geographic Location on Outcomes in Allogeneic Transplant

Impact of Chronic Graft-Versus-Host Disease on Non-Relapse Mortality

Improvement in Survival of AML and MDS Patients Following Allogeneic Transplant: A Long-Term Institutional Experience

Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma

Survival Implications of Opioid Use after Blood and Marrow Transplantation

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only